# Replimune

Source: https://onco.cc/companies/replimune/  
OnCo record `replimune` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Oncolytic virus company whose RP1 (Tudriqev) was approved in August 2026 after an initial FDA rejection.

## Summary

Replimune, based in Woburn, Massachusetts, and listed as REPL, is the oncolytic virus company whose RP1, or vusolimogene oderparepvec, was approved in August 2026 as Tudriqev after an initial FDA rejection. RP1 is an oncolytic virus for melanoma and cutaneous squamous cell carcinoma, and RP2, which expresses an anti-CTLA-4 antibody, is being tested in uveal melanoma. OnCo links it to melanoma and cutaneous squamous cell carcinoma, to the oncolytic virus technology, to the bottleneck of cold tumours, and to the idea of oncolytic viruses that make interleukin-12 only inside the tumour. Whether an approval won after a rejection translates into adoption alongside checkpoint inhibitors is the open question. Vusolimogene oderparepvec has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Woburn, MA
- Type: biotech
- Website: https://www.replimune.com
- Ticker: REPL

## Sources

- Official website: https://www.replimune.com

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Vusolimogene oderparepvec](https://onco.cc/drugs/vusolimogene-oderparepvec/)
- trials: [A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P](https://onco.cc/trials/nct06581406/), [Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer](https://onco.cc/trials/nct04050436/), [Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)](https://onco.cc/trials/nct03767348/), [Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC](https://onco.cc/trials/nct05733598/), [Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies](https://onco.cc/trials/nct04349436/), [VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]](https://onco.cc/trials/nct06264180/)
- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/)
- ideas: [Oncolytic viruses that make interleukin-12 only inside the tumour](https://onco.cc/ideas/idea-bio2-oncolytic-regulated-il12/)
- key papers: [IGNYTE: an engineered herpes virus with nivolumab in melanoma that had already failed anti-PD-1 therapy](https://onco.cc/key-papers/paper-wong-ignyte-rp1-nivolumab-jco-2025/)
- companies: [Bain Capital Life Sciences](https://onco.cc/companies/bain-capital-life-sciences/)

---
JSON: https://onco.cc/api/v1/entities/replimune.json